A single-dose, open-label, two-treatment, two-period, two-sequence, two-way cross-over bioavailability & bioequivalence study to compare two formulation of Olmesartan 40 mg in healthy adults in fed state
Mohit Changani, Ameet Soni, Ambrish Singh, Harsh Choksi, Lokesh Kumar